A.-M. Chollet et al. / Bioorg. Med. Chem. Lett. 11 (2001) 295±299
299
4. MacPherson, L. J.; Bayburt, E. K.; Capparelli, M. P.;
Carroll, B. J.; Goldstein, R.; Justice, M. R.; Zhu, L.; Hu, S. I.;
Melton, R. A.; Fryer, L.; Goldberg, R. L.; Doughty, J. R.;
Spirito, S.; Blancuzzi, V.; Wilson, D.; O'Byrne, E. M.; Ganu,
V.; Parker, D. T. J. Med. Chem. 1997, 40, 2525. Broadhurst,
M. J.; Brown, P. A.; Lawton, G.; Ballantyne, N.; Borkakoti,
N.; Bottomley, K. M. K.; Cooper, M. I.; Eatherton, A. J.;
Kilford, I. R.; Malsher, P. J.; Nixon, J. S.; Lewis, E. J.; Sutton,
B. M.; Johnson, W. H. J. Med. Chem. 1997, 40, 2525.
5. (a) Broadhurst, M. J.; Brown, P. A.; Ballantyne, N.; Bor-
kakoti, N.; Bottomley, K. M. K.; Cooper, M. I.; Eartherton,
A. J.; Kilford, I. R.; Malsher, P. J.; Nixon, J. S.; Lewis, E. J.;
Sutton, B. M.; Johnson, W. H. Bioorg. Med. Chem. Lett. 1997,
7, 2299. (b) Lewis, E. J.; Bishop, J.; Bottomley, K. M. K.;
Bradshaw, D.; Brewster, M.; Broadhurst, M. J.; Brown, P. A.;
Budd, J. M.; Elliott, L.; Greenham, A. K.; Johnson, W. H.;
Nixon, J. S.; Rose, F.; Sutton, B.; Wilson, K. Brit. J. Phar-
macol. 1997, 121, 540.
P. L.; Norton, D.; Salovich, J. M.; Schoenen, F. J.; Ward, P. J.
Med. Chem. 1994, 37, 674. (b) Hunter, D. J.; Bird, J.; Cassidy,
F.; De Mello, R. C.; Harper, G. P.; Karran, E. H.; Markwell,
R. E.; Miles-Williams, A. J.; Ward, R. W. Bioorg. Med. Chem.
Lett. 1994, 24, 2833. (c) Xue, C.-B.; He, X.; Roderick, J.;
DeGrado, W. F.; Decicco, C.; Copeland, R. A. Bioorg. Med.
Chem. Lett. 1996, 4, 379. (d) Robinson, R. P.; Cronin, B. J.;
Donahue, K. M.; Jones, B. P.; Lopresti-Morrow, L. L.;
Mitchell, P. G.; Rizzi, J. P.; Reeves, L. M.; Yocum, S. A.
Bioorg. Med. Chem. Lett. 1996, 14, 1725.
17. Mitsunobu, O. Synthesis 1981, 1.
18. McArthur, C. R.; Worster, P. M.; Okon, A. U. Synth.
Commun. 1983, 13, 11.
19. (a) Hudlicky, M. Oxidations in Organic Chemistry, ACS
Monograph 186, 1990. (b) Henry, J. R.; Weinreb, S. M. J.
Org. Chem. 1993, 58, 4745. (c) Warnell, J. L.; Shriner, R. L. J.
Am. Chem. Soc. 1956, 79, 3165.
20. Loet, A.; Zhang, H. X. Int. J. Pept. Protein Res. 1993,
42, 346.
21. Greene, T. Protective Groups in Organic Synthesis; John
Wiley: New York, 1990; pp 250±252.
22. All new compounds in Table 2 gave spectroscopic data
(IR, NMR) and analysis (CHN) in agreement with the
assigned structures.
6. Rasmussen, H. S.; McCann, P. P. Pharmacol. Ther. 1997,
75, 69.
7. (a) Santos, O.; Mcdermott, C. D.; Daniels, R. G.; Appelt,
K. Clin. Exp. Metastasis 1997, 15, 499. (b) Shalinsky, D. R.;
Brekker, J.; Zou, H.; Kolis, S.; Wood, A.; Webber, S.; Appelt,
K. Invest. New Drug 1999, 16, 303.
8. (a) Heath, E. I.; Grochow, L. B. Drugs 2000, 1043. (b)
Brown, P. D. APMIS 1999, 107, 174.
23. Rivero, I. A.; Somanathan, R.; Hellberg, L. H. Synth.
Commun. 1998, 28, 2077.
9. Borden, P.; Solimar, D.; Swcharczuk, A.; Lindman, B.;
Cannon, P.; Heller, R. A. J. Biol. Chem. 1996, 271, 23577.
10. Massova, I.; Fridman, R.; Mobashery, S. J. Mol. Model.
1997, 1, 17 and references cited therein.
11. (a) Beckett, R. P.; Whittaker, M. Exp. Opin. Ther. Patents
1998, 8, 259. (b) Whittaker, M.; Floyd, C. D.; Brown, P.;
Geating, A. J. H. Chem. Rev. 1999, 99, 2735.
12. (a) Krumme, D.; Wenzel, H.; Tschesche, H. FEBS Lett.
1998, 436, 209. (b) Esser, C. K.; Bugianesi, R. L.; Caldwell,
C. G.; Chapman, K. T.; Durette, P. L.; Girotra, N. N.;
Kopka, I. E.; Lanza, T. J.; Levorse, D. A.; MacCoss, M.;
Owens, K. A.; Ponpipom, M. M.; Simeone, J. S.; Harrison,
R. K.; Niedzwiecki, L.; Becker, J. W.; Marcy, A. I.; Axel,
M. G.; Christen, A. J.; McDonnell, J.; Moore, V. L.; Ols-
zewski, J. M.; Saphos, C.; Visco, D. M.; Shen, F.; Colletti, A.;
Krieter, P. A.; Hagmann, W. K. J. Med. Chem. 1997, 40, 1026.
(c) Bottomley, K. M.; Johnson, W. H.; Walter, D. S. J.
Enzyme Inhib. 1998, 2, 79.
13. Hajduk, P. J.; Sheppard, G.; Nettesheim, D. G.; Olejnic-
zak, E. T.; Shuker, S. B.; Meadows, R. P.; Steinman, D. H.;
Carrera, G. M.; Marcotte, P. A., Jr.; Severin, J.; Walter, K.;
Smith, H.; Gubbins, E.; Simmer, R.; Holzman, T. F.; Morgan,
D. W.; Davidsen, S. K.; Summers, J. B.; Fesik, S. W. J. Am.
Chem. Soc. 1997, 119, 5818.
24. Farina, V.; Krishnamurthy, V.; Scott, W. J. Org. React.
1997, 50.
25. Tschaen, D. M.; Desmond, R.; King, A. O.; Fortin, M. C.;
Pipik, B.; King, S.; Verhoeven, T. R. Synth. Commun. 1994,
24, 887.
26. Human puri®ed MMPs were purchased from Calbiochem
(MMP-1), Boehringer (MMP-2,9), Valbiotech (MMP-3) and
from Pr Murphy (U. East Anglia, MMP-13). Inhibition of
MMPs, except MMP-3, was quanti®ed as described previously
(Anal. Biochem. 1993, 212, 58) by using the substrate Dnp-Pro-
Cha-Gly-Cys(ME)-His-Ala-Lys(Nma)-NH2 (Bachem) which is
cleaved between amino acids Gly and Cys by APMA-activated
MMPs. For MMP-3 assays, the following substrate is used: (7-
methoxycoumarine-4-yl)-Arg-Pro-Lys-Pro-Tyr-Ala-Nva-Trp-
Met-Lys(Dnp)-NH2 which is cleaved between Ala and Nva
(reference M-2105 from Bachem) (Biochemistry 1992, 31, 12618).
The ¯uorescent cleavage product was measured with a ¯uo-
rometer (Spectro¯uor Plus, Tecan) equipped with a combination
of 340 and 440 nm ®lters for excitation and emission, respectively.
27. Adapted from Biochem. Biophys. Res. Commun. 2000, 267,
438; SO4 labeled cartilage explants were stimulated for 1 day
with 10 ng/mL interleukin-1b (Sigma) in order to induce
MMP production. Explants were then cultured for one extra
4
day in the absence (control) or presence of 5Â10 M APMA
14. Johnson, W. S.; Werthemann, L.; Bartlett, W. R.; Brock-
som, T. J.; Li, T. T. J. Am. Chem. Soc. 1970, 92, 741.
15. Wilk, B. K. Synth. Commun. 1993, 23, 2481.
16. (a) Brown, F. K.; Brown, P. J.; Bickett, D. M.; Chambers,
C. L.; Davies, H. G.; Deaton, D. N.; Drewry, D.; Foley, M.;
McElroy, A. B.; Gregson, M.; McGeehan, G. M.; Myers,
(MMP activator)ÆMMP inhibitors at concentrations ranging
9
6
between 10 and 10 M (n=8/group). Proteoglycan degra-
dation was quanti®ed as % radioactivity released by each
explant, and the eect of the products was calculated as %
inhibition of APMA-induced, MMP-dependent degradation.
28. Khokha, R. J. Natl. Cancer Inst. 1994, 86, 299.